PEGASYS Drug Summary Page

Pegasys (peginterferon alfa-2a) MONOTHERAPY

Comparison of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C- 8/08/06

Experimental Oral Protease Inhibitor VX-950 from Vertex Produces Rapid and Dramatic Reduction in HCV RNA in Combination with Pegylated Interferon Alfa-2a (Pegasys) - 1/10/06

Suppression of Blood Cell Formation during Chronic Hepatitis C Therapy with Different Interferon Alfa Mono- and Combination Therapy Regimens - 7/15/05

Response to Interferon Alfa Therapy in a Patient with HCV-related Arthritis - 7/13/05

Peginterferon alfa-2a (Pegasys) Does Not Alter the Pharmacokinetics of Methadone - 3/18/05

PEG-Intron Drug Summary Page

PEG-Intron (peginterferon alfa-2b) MONOTHERAPY


Long-term, Low-Dose Treatment with Pegylated Interferon Alfa-2b (PegIntron) Monotherapy Leads to a Reduction in Fibrosis and Inflammatory Scores in Prior Non-responders - 11/13/07

Treatment with Low-dose Pegylated Interferon Alfa-2b (PegIntron) Does Not Adversely Affect Quality of Life over a 2-year Period: The COPILOT Trial - 11/06/07

Final Results of the Canadian Pegylated Interferon Alfa-2b (PegIntron) Prospective Optimal Weight-based Dosing Response (POWeR) Study - 11/06/07

Short-course Pegylated Interferon for Acute HCV Infection   - 2/09/07

Comparison of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C- 8/08/06

Efficacy of Low-dose Peg-Intron - 8/04/06

Response to Interferon Alfa Therapy in a Patient with HCV-related Arthritis - 7/13/05

Optimal Dosing Frequency of Pegylated Interferon Alfa-2b (PegIntron) Monotherapy - 6/29/05

Acute HCV Infection: Diagnosis, Natural History and Treatment - 6/20/05